Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service prostatectomy & nephrectomy cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (203 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 19 | 1,677 | 47% |
| 2020 | 23 | 1,613 | 49% |
| 2021 | 24 | 1,772 | 51% |
| 2022 | 22 | 1,814 | 53% |
| 2023 | 20 | 1,676 | 56% |
| 2024 | 27 | 1,659 | 58% |
| 2025 from claims | – | 1,729 1,587–1,829 | 59% |
| 2026 forecast | – | 1,782 1,568–2,056 | 59% |
| 2027 forecast | – | 1,811 1,548–2,158 | 59% |
| 2028 forecast | – | 1,840 1,535–2,253 | 60% |
| 2029 forecast | – | 1,869 1,527–2,344 | 60% |
| 2030 forecast | – | 1,899 1,521–2,433 | 61% |
Robotic radical prostatectomy and laparoscopic nephrectomy. Professional codes (what the surgeon bills): CPT 55866, 50543, 50545, 50546, 50548; the hospital bills MS-DRG 707, 708, 656, 657, 658.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 62% of the cases CMS names in Pennsylvania; 17 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 45% inpatient hospital, 55% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,800 | ~780 | ~1,000 |
| 2027 · ~1,800 | ~780 | ~1,000 |
| 2028 · ~1,800 | ~780 | ~1,100 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 43% (45% in 2025), hospital outpatient about 57% (55% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 33 | 2,271−2.4%/yr | −2.4%/yr | 1.4 | 0% | 2,710 in 2030+3%/yr |
| Massachusetts | 10 | 885−2.7%/yr | −2.7%/yr | 1.0 | 0% | 1,070 in 2030+3.2%/yr |
| New Jersey | 9 | 867+0.5%/yr | +0.5%/yr | 0.9 | 0% | 1,060 in 2030+3.4%/yr |
| Connecticut | 4 | 324+1.3%/yr | +1.3%/yr | 1.1 | 0% | 480 in 2030+6.6%/yr |
| New Hampshire | 5 | 194−3.3%/yr | −3.3%/yr | 0.9 | 0% | 300 in 2030+7.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Kidney stone management | 164 | 6,776−2%/yr | −2%/yr | 5.00.9× | 12% | 6,810 in 2030+0.1%/yr |
| BPH procedures | 78 | 5,698−7.3%/yr | −7.3%/yr | 4.21.0× | 31% | 4,890 in 2030−2.5%/yr |
| Hysterectomy, hysteroscopy & ablation | 52 | 4,366−2%/yr | −2%/yr | 3.51.1× | 10% | 4,620 in 2030+0.9%/yr |
| Incontinence, prolapse & sacral neuromodulation | 45 | 2,928+2.4%/yr | +2.4%/yr | 2.11.2× | 8% | 3,450 in 2030+2.8%/yr |
Prostatectomy & nephrectomy in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Intuitive Surgical leads with 99% of company spending on these surgeons in 2025, level with 2024.
In 2025, 2 companies reported engagement with Pennsylvania’s surgeons worth $345K in consulting, speaking, meals and travel tied to these products, about $13K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 9 clearances and approvals in the category, 12 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.